Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating whether treating all individuals who test positive for gambiense human African trypanosomiasis gHAT serology with acoziborole can stop the spread of the disease in affected villages over three years. This study also aims to collect additional safety data for acoziborole in people who are seropositive but do not have confirmed parasitological infection. The study is coordinated by the Institute of Tropical Medicine, Belgium, with the Drugs for Neglected Diseases initiative overseeing the safety trial portion. Participants receive a single oral dose of acoziborole, with adults and adolescents aged 15 and older taking 960 mg and children aged 11 to 14 years weighing at least 30 kg taking 640 mg. Treatment is given either with or without food on the first day of the study. Follow-up visits occur at three days and three months after treatment to monitor safety and response. No placebo or active comparison treatment is used. During the study, participants are regularly assessed through home or study center visits. Researchers monitor safety, collect health information, and evaluate the interruption of disease transmission over four years. Participants must comply with follow-up schedules and agree not to join other clinical trials during the study period. The overall participation may last several years to assess both safety and impact on disease transmission.